Stevens-Johnson Syndrome Antimicrobial

This study has been completed.
Sponsor:
Information provided by:
University of Pernambuco
ClinicalTrials.gov Identifier:
NCT00844038
First received: February 12, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
  Purpose

Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacterial infections and mainly the administration of medicines, in general painkillers and antibiotics. The objective of this work is report the emergence of ulcerative vesicle -bubble chronic disease in areas of lips, gum, tongue and genital mucous membrane in a 26 year-old patient, leucoderma and masculine gender, in treatment of breathing infection with sulfametoxazol-trimetropima, having been diagnosed as syndrome of Steven-Johnson.


Condition
Stevens-Johnson Syndrome

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Stevens-Johnson Syndrome Associated With Antimicrobial

Resource links provided by NLM:


Further study details as provided by University of Pernambuco:

Enrollment: 1
Study Start Date: August 2008
Study Completion Date: December 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)

Detailed Description:

Among the serious medicaments reactions, there are as great representative the Mucocutaneous Disorders immunological mediated. Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacterial infections and mainly the administration of medicines, in general painkillers and antibiotics. The objective of this work is report the emergence of ulcerative vesicle -bubble chronic disease in areas of lips, gum, tongue and genital mucous membrane in a 26 year-old patient, leucoderma and masculine gender, in treatment of breathing infection with sulfametoxazol-trimetropima, having been diagnosed as syndrome of Steven-Johnson.

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

1

Criteria

Inclusion Criteria:

  • Stevens-Johnson syndrome associated with antimicrobial

Exclusion Criteria:

  • Not sick
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00844038

Locations
Brazil
University of Pernambuco
Recife, Pernambuco, Brazil, 52021220
Sponsors and Collaborators
University of Pernambuco
Investigators
Principal Investigator: Edwaldo Dr Dourado, Doctor University of Pernambuco
  More Information

Publications:
Responsible Party: Stevens-Johnson syndrome associated with antimicrobial, University of Pernambuco
ClinicalTrials.gov Identifier: NCT00844038     History of Changes
Other Study ID Numbers: SSJ1, 558187121279
Study First Received: February 12, 2009
Last Updated: February 12, 2009
Health Authority: Brazil: Ethics Committee

Keywords provided by University of Pernambuco:
Steven-Johnson syndrome
erythema multiform
autoimmune disease

Additional relevant MeSH terms:
Syndrome
Stevens-Johnson Syndrome
Disease
Pathologic Processes
Stomatitis
Mouth Diseases
Stomatognathic Diseases
Drug Eruptions
Dermatitis
Skin Diseases
Erythema Multiforme
Erythema
Skin Diseases, Vesiculobullous
Drug Hypersensitivity
Hypersensitivity
Immune System Diseases
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 19, 2014